Dorsey Wright & Associates Verona Pharma PLC Transaction History
Dorsey Wright & Associates
- $378 Million
- Q1 2025
A detailed history of Dorsey Wright & Associates transactions in Verona Pharma PLC stock. As of the latest transaction made, Dorsey Wright & Associates holds 70,671 shares of VRNA stock, worth $5.9 Million. This represents 1.19% of its overall portfolio holdings.
Number of Shares
70,671
Previous 78,646
10.14%
Holding current value
$5.9 Million
Previous $3.65 Million
22.84%
% of portfolio
1.19%
Previous 0.91%
Shares
3 transactions
Others Institutions Holding VRNA
# of Institutions
291Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$548 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$460 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$327 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$288 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$241 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $5.08B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...